REGN vs. VRTX, GSK, BMY, SNY, ZTS, PFE, TAK, ABT, RPRX, and BGNE
Should you be buying Regeneron Pharmaceuticals stock or one of its competitors? The main competitors of Regeneron Pharmaceuticals include Vertex Pharmaceuticals (VRTX), GSK (GSK), Bristol-Myers Squibb (BMY), Sanofi (SNY), Zoetis (ZTS), Pfizer (PFE), Takeda Pharmaceutical (TAK), Abbott Laboratories (ABT), Royalty Pharma (RPRX), and BeiGene (BGNE). These companies are all part of the "pharmaceutical preparations" industry.
Vertex Pharmaceuticals (NASDAQ:VRTX) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, community ranking, dividends and institutional ownership.
Vertex Pharmaceuticals has a net margin of 39.46% compared to Vertex Pharmaceuticals' net margin of 29.45%. Regeneron Pharmaceuticals' return on equity of 23.08% beat Vertex Pharmaceuticals' return on equity.
91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 8.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Regeneron Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Vertex Pharmaceuticals has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500.
Vertex Pharmaceuticals received 61 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 75.63% of users gave Vertex Pharmaceuticals an outperform vote while only 66.59% of users gave Regeneron Pharmaceuticals an outperform vote.
Vertex Pharmaceuticals presently has a consensus target price of $432.18, indicating a potential downside of 2.93%. Regeneron Pharmaceuticals has a consensus target price of $989.36, indicating a potential upside of 0.72%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Vertex Pharmaceuticals.
In the previous week, Regeneron Pharmaceuticals had 14 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 30 mentions for Regeneron Pharmaceuticals and 16 mentions for Vertex Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.00 beat Vertex Pharmaceuticals' score of 0.65 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.
Summary
Vertex Pharmaceuticals and Regeneron Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Regeneron Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding REGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Regeneron Pharmaceuticals Competitors List
Related Companies and Tools
